Anzeige
Mehr »
Samstag, 13.06.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJVC | ISIN: KYG4403H1002 | Ticker-Symbol: 6XY
Tradegate
12.06.26 | 11:07
1,130 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
HBM HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
HBM HOLDINGS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,1101,14013:05
1,1001,15012.06.

Aktuelle News zur HBM HOLDINGS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoHarbour BioMed Adds Luisa Salter-Cid as Scientific Advisor1
MiHBM HOLDINGS-B: IND Application for HBM7004 for Advanced Solid Tumors Approved by NMPA5
MiHBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF IND APPLICATION FOR HBM7004 FOR THE TREATMENT OF ADVANCED SOLID TUMORS1
DiHarbour BioMed: First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody144COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease HBM9378/WIN378 is currently being evaluated...
► Artikel lesen
DiHBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - FIRST PATIENTS DOSED IN PHASE II SIRIUS COPD STUDY OF HBM9378/WIN378, A FULLY HUMAN ULTRA LONG-ACTING ...-
HBM HOLDINGS Aktie jetzt für 0€ handeln
19.05.HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN1
18.05.HBM HOLDINGS-B Discloses Preclinical Data of AI Candidate Drug for Obesity Treatment1
18.05.Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate847Hu-mAtrIx-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM...
► Artikel lesen
18.05.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - RELEASE OF PRECLINICAL DATA FOR LET003, FIRST AI-ENABLED DRUG CANDIDATE, A NEXT-GENERATION ACVR2A/2B-TARGETING ...2
13.05.HBM HOLDINGS-B (02142): INSIDE INFORMATION - INVESTIGATION AGAINST AN INDEPENDENT NON-EXECUTIVE DIRECTOR2
12.05.HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN-
08.05.Harbour BioMed's IND for HBM7004 Cleared by FDA1
08.05.Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors149CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 8, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company...
► Artikel lesen
08.05.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - U.S. FDA IND CLEARANCE FOR HBM7004 FOR THE TREATMENT OF ADVANCED SOLID TUMORS-
04.05.HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN1
28.04.HBM HOLDINGS-B (02142): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTIFICATION OF PUBLICATION OF 2025 ANNUAL REPORT, CIRCULAR ...-
28.04.HBM HOLDINGS-B (02142): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF 2025 ANNUAL REPORT, CIRCULAR, PROXY FORM ...-
28.04.HBM HOLDINGS-B (02142): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING-
28.04.HBM HOLDINGS-B (02142): NOTICE OF ANNUAL GENERAL MEETING-
28.04.HBM HOLDINGS-B (02142): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT ...3
Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1